BIOMARKER:

EGFR exon 19 deletion

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Lung Adenocarcinoma

Lung Non-Squamous Non-Small Cell Cancer

Small Cell Lung Cancer

Lung Non-Small Cell Squamous Cancer

Lung Cancer

Thymic Carcinoma

amivantamab-vmjw

EGFR exon 19 deletion|Non Small Cell Lung Cancer|amivantamab-vmjw

EGFR exon 19 deletion|Lung Non-Squamous Non-Small Cell Cancer|amivantamab-vmjw

bevacizumab + erlotinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|bevacizumab + erlotinib

EGFR inhibitor

EGFR exon 19 deletion|Non Small Cell Lung Cancer|EGFR inhibitor

EGFR exon 19 deletion|Lung Adenocarcinoma|EGFR inhibitor

EGFR exon 19 deletion|Lung Non-Small Cell Squamous Cancer|EGFR inhibitor

Tyrosine kinase inhibitor

EGFR exon 19 deletion|Non Small Cell Lung Cancer|Tyrosine kinase inhibitor

PD-L1 inhibitor

EGFR exon 19 deletion|Non Small Cell Lung Cancer|PD-L1 inhibitor

gefitinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|gefitinib

EGFR exon 19 deletion|Lung Adenocarcinoma|gefitinib

EGFR exon 19 deletion|Small Cell Lung Cancer|gefitinib

EGFR exon 19 deletion|Lung Cancer|gefitinib

PD1 inhibitor

EGFR exon 19 deletion|Non Small Cell Lung Cancer|PD1 inhibitor

osimertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|osimertinib

EGFR exon 19 deletion|Lung Non-Squamous Non-Small Cell Cancer|osimertinib

EGFR exon 19 deletion|Lung Adenocarcinoma|osimertinib

EGFR exon 19 deletion|Small Cell Lung Cancer|osimertinib

bevacizumab + atezolizumab

EGFR exon 19 deletion|Non Small Cell Lung Cancer|bevacizumab + atezolizumab

EGFR exon 19 deletion|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab + atezolizumab

Immunotherapy

EGFR exon 19 deletion|Non Small Cell Lung Cancer|Immunotherapy

gefitinib + rivoceranib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|gefitinib + rivoceranib

anlotinib + icotinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|anlotinib + icotinib

EGFR exon 19 deletion|Lung Non-Squamous Non-Small Cell Cancer|anlotinib + icotinib

EGFR exon 19 deletion|Lung Adenocarcinoma|anlotinib + icotinib

gefitinib + ramucirumab

EGFR exon 19 deletion|Non Small Cell Lung Cancer|gefitinib + ramucirumab

befotertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|befotertinib

brigatinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|brigatinib

EGFR exon 19 deletion|Lung Adenocarcinoma|brigatinib

aumolertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|aumolertinib

EGFR exon 19 deletion|Lung Adenocarcinoma|aumolertinib

icotinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|icotinib

EGFR exon 19 deletion|Thymic Carcinoma|icotinib

afatinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|afatinib

EGFR exon 19 deletion|Lung Adenocarcinoma|afatinib

anlotinib + aumolertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|anlotinib + aumolertinib

dacomitinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|dacomitinib

erlotinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|erlotinib

erlotinib + ramucirumab

EGFR exon 19 deletion|Non Small Cell Lung Cancer|erlotinib + ramucirumab

amivantamab-vmjw + lazertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|amivantamab-vmjw + lazertinib

furmonertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|furmonertinib

lazertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|lazertinib

osimertinib + gefitinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|osimertinib + gefitinib

EGF816

EGFR exon 19 deletion|Non Small Cell Lung Cancer|EGF816

U3-1402

EGFR exon 19 deletion|Non Small Cell Lung Cancer|U3-1402

bevacizumab + osimertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|bevacizumab + osimertinib

tislelizumab

EGFR exon 19 deletion|Non Small Cell Lung Cancer|tislelizumab

durvalumab

EGFR exon 19 deletion|Non Small Cell Lung Cancer|durvalumab

bevacizumab

EGFR exon 19 deletion|Non Small Cell Lung Cancer|bevacizumab

BBT-176

EGFR exon 19 deletion|Non Small Cell Lung Cancer|BBT-176

icotinib + furmonertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|icotinib + furmonertinib

erlotinib + anlotinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|erlotinib + anlotinib

afatinib + DFP-14323

EGFR exon 19 deletion|Non Small Cell Lung Cancer|afatinib + DFP-14323

olaparib + gefitinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|olaparib + gefitinib

ensartinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|ensartinib

alectinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|alectinib

lorlatinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|lorlatinib

gefitinib + fruquintinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|gefitinib + fruquintinib

anlotinib + APL-502

EGFR exon 19 deletion|Non Small Cell Lung Cancer|anlotinib + APL-502

gefitinib + anlotinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|gefitinib + anlotinib

bevacizumab + gefitinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|bevacizumab + gefitinib

osimertinib + afatinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|osimertinib + afatinib

icotinib + aumolertinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|icotinib + aumolertinib

KN046

EGFR exon 19 deletion|Non Small Cell Lung Cancer|KN046

AZD3759

EGFR exon 19 deletion|Non Small Cell Lung Cancer|AZD3759

AUY922

EGFR exon 19 deletion|Non Small Cell Lung Cancer|AUY922

osimertinib + TP-0903

EGFR exon 19 deletion|Non Small Cell Lung Cancer|osimertinib + TP-0903

osimertinib + anlotinib

EGFR exon 19 deletion|Lung Adenocarcinoma|osimertinib + anlotinib

camrelizumab + rivoceranib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|camrelizumab + rivoceranib

VT-104

EGFR exon 19 deletion|Lung Cancer|VT-104

erlotinib + ado-trastuzumab emtansine

EGFR exon 19 deletion|Non Small Cell Lung Cancer|erlotinib + ado-trastuzumab emtansine

lenalidomide

EGFR exon 19 deletion|Non Small Cell Lung Cancer|lenalidomide

CH7233163

EGFR exon 19 deletion|Non Small Cell Lung Cancer|CH7233163

BMS-722782

EGFR exon 19 deletion|Lung Cancer|BMS-722782

H002

EGFR exon 19 deletion|Non Small Cell Lung Cancer|H002

BI-4020

EGFR exon 19 deletion|Non Small Cell Lung Cancer|BI-4020

EGFR exon 19 deletion|Non Small Cell Lung Cancer|

ERAS-801

EGFR exon 19 deletion|Non Small Cell Lung Cancer|ERAS-801

durvalumab + gefitinib

EGFR exon 19 deletion|Non Small Cell Lung Cancer|durvalumab + gefitinib

VRN11

EGFR exon 19 deletion|Non Small Cell Lung Cancer|VRN11